ReviewInternational journal of molecular sciences2018
A History of the Pharmacological Treatment of Bipolar Disorder.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Clinical Lactation Studies of Lithium: A Systematic Review.Frontiers in pharmacology · 2019Pooled it
- Comprehensive Review and Meta-Analysis of Psychological and Pharmacological Treatment for Intermittent Explosive Disorder: Insights From Both Case Studies and Randomized Controlled Trials.Clinical psychology & psychotherapyPooled it
- Prescribing factors influencing hospital length of stay in patients initiating lithium therapy for acute bipolar or schizoaffective mood episodes.The mental health clinician · 2026Article
- Lurasidone-Associated Urinary Retention in a Patient With Bipolar Affective Disorder: A Case Report.Case reports in psychiatry · 2026Article
- Transcranial temporal interference stimulation for treating bipolar disorder with depressive episodes: a feasibility Study.Molecular psychiatry · 2025Article
- Analysis of Antipsychotic Drug Use Patterns and Safety in Patients With Bipolar Disorder.Psychiatry investigation · 2025Article
- Valproate independently activates Snf1, inhibits TORC1, and induces repression of INO1 transcription by increasing nuclear localization of Opi1.Scientific reports · 2025Article
- Article
- Attitudes toward lithium prescription among psychiatrists in Saudi Arabia: a cross-sectional study.Frontiers in psychiatry · 2025Article
- Pre- and Postnatal Valproate Exposure Affects Brain Development.Current topics in behavioral neurosciences · 2025Review
- Global perspectives on bipolar disorder treatment: in-depth comparative analysis of international guidelines for medication selection.BJPsych open · 2024Review
- Direct Immersion-Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders.Molecules (Basel, Switzerland) · 2024Article
- Initial dosage optimization of olanzapine in patients with bipolar disorder based on model-informed precision dosing: a study from the real world.Frontiers in pharmacology · 2024Article
- Ethical and Legal Aspects of Treating Bipolar Disorder.Focus (American Psychiatric Publishing) · 2023Article
- Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy.Cureus · 2023Review
- The History of Drug Development in Psychiatry: A Lesson in Serendipity.Advances in neurobiology · 2023Article
- Disease-specific differences in gene expression, mitochondrial function and mitochondria-endoplasmic reticulum interactions in iPSC-derived cerebral organoids and cortical neurons in schizophrenia and bipolar disorder.Discover mental health · 2023Article
- Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Article
- Review
- Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder.Bipolar disorders · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this paper, the authors review the history of the pharmacological treatment of bipolar disorder, from the first nonspecific sedative agents introduced in the 19th and early 20th century, such as solanaceae alkaloids, bromides and barbiturates, to John Cade's experiments with lithium and the beginning of the so-called "Psychopharmacological Revolution" in the 1950s. We also describe the clinical studies and development processes, enabling the therapeutic introduction of pharmacological agents currently available for the treatment of bipolar disorder in its different phases and manifestations. Those drugs include lithium salts, valproic acid, carbamazepine, new antiepileptic drugs, basically lamotrigine and atypical antipsychotic agents (olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, asenapine, cariprazine and lurasidone). Finally, the socio-sanitary implications derived from the clinical introduction of these drugs are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.